The ClinicalTrials.gov Results Database - Update and Key Issues

被引:560
作者
Zarin, Deborah A. [1 ]
Tse, Tony [1 ]
Williams, Rebecca J. [1 ]
Califf, Robert M. [2 ]
Ide, Nicholas C. [1 ]
机构
[1] NIH, Lister Hill Natl Ctr Biomed Commun, Natl Lib Med, Bethesda, MD 20894 USA
[2] Duke Univ, Duke Translat Med Inst, Durham, NC USA
关键词
TRIALS; GLOBALIZATION; BIAS;
D O I
10.1056/NEJMsa1012065
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND The ClinicalTrials.gov trial registry was expanded in 2008 to include a database for reporting summary results. We summarize the structure and contents of the results database, provide an update of relevant policies, and show how the data can be used to gain insight into the state of clinical research. METHODS We analyzed ClinicalTrials.gov data that were publicly available between September 2009 and September 2010. RESULTS As of September 27, 2010, ClinicalTrials.gov received approximately 330 new and 2000 revised registrations each week, along with 30 new and 80 revised results submissions. We characterized the 79,413 registry and 2178 results of trial records available as of September 2010. From a sample cohort of results records, 78 of 150 (52%) had associated publications within 2 years after posting. Of results records available publicly, 20% reported more than two primary outcome measures and 5% reported more than five. Of a sample of 100 registry record outcome measures, 61% lacked specificity in describing the metric used in the planned analysis. In a sample of 700 results records, the mean number of different analysis populations per study group was 2.5 (median, 1; range, 1 to 25). Of these trials, 24% reported results for 90% or less of their participants. CONCLUSIONS ClinicalTrials.gov provides access to study results not otherwise available to the public. Although the database allows examination of various aspects of ongoing and completed clinical trials, its ultimate usefulness depends on the research community to submit accurate, informative data.
引用
收藏
页码:852 / 860
页数:9
相关论文
共 29 条
[1]  
[Anonymous], 2009, Official Journal of the European Union, DOI DOI 10.3000/17252555.L_2009.342.ENG
[2]   ETHICS AND CLINICAL RESEARCH [J].
BEECHER, HK .
NEW ENGLAND JOURNAL OF MEDICINE, 1966, 274 (24) :1354-&
[3]   Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov [J].
Bourgeois, Florence T. ;
Murthy, Srinivas ;
Mandl, Kenneth D. .
ANNALS OF INTERNAL MEDICINE, 2010, 153 (03) :158-U48
[4]   Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results [J].
Chan, An-Wen .
PLOS MEDICINE, 2008, 5 (11) :1533-1535
[5]   Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research [J].
Chan, AW ;
Krieza-Jeric, K ;
Schmid, I ;
Altman, DG .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (07) :735-740
[6]  
Claire B, 2000, N Engl J Med, V343, P1520, DOI [DOI 10.1056/NEJME058314, 10.1056/NEJMe058314.73, DOI 10.1056/NEJM200011233432103, 10.1056/NEJM200011233432103]
[7]  
*CLIN TRIALS TRANS, IMPR PUBL INT US AGG
[8]  
*CLINICALTRIALS GO, 2010, PROT DAT EL IN PRESS
[9]  
Consolidated Standards of Reporting Trials (CONSORT) Group, CONS STAND REP TRIAL
[10]   Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8 [J].
Curfman, GD ;
Morrissey, S ;
Drazen, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (26) :2813-2814